Targeted News Service

Institute for Clinical & Economic Review to Assess Treatments for Atopic Dermatitis
December 12, 2020

BOSTON, Massachusetts, Dec. 12 -- The Institute for Clinical and Economic Review issued the following announcement on Dec. 10:

The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of:

* Abrocitinib (Pfizer)

* Tralokinumab (LEO Pharma)

* Baricitinib (Olumiant(R), Eli Lilly, Incyte)

* Upadacitinib (Rinvoq(R), AbbVie)

* Ruxolitinib (Incy . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form